Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Non-Current Assets (2019 - 2026)

C4 Therapeutics has reported Other Non-Current Assets over the past 8 years, most recently at $3.4 million for Q1 2026.

  • For Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $3.4 million; the TTM value through Mar 2026 reached $3.4 million, changed 0.0%, while the annual FY2025 figure was $3.7 million, 6.97% up from the prior year.
  • Other Non-Current Assets for Q1 2026 was $3.4 million at C4 Therapeutics, down from $3.7 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $3.7 million in Q4 2025 and troughed at $211000.0 in Q3 2025.
  • A 5-year average of $3.2 million and a median of $3.4 million in 2023 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 156.97% in 2022 and later plummeted 93.87% in 2025.
  • Year by year, Other Non-Current Assets stood at $3.3 million in 2022, then grew by 5.0% to $3.4 million in 2023, then changed by 0.0% to $3.4 million in 2024, then increased by 6.97% to $3.7 million in 2025, then fell by 6.52% to $3.4 million in 2026.
  • Business Quant data shows Other Non-Current Assets for CCCC at $3.4 million in Q1 2026, $3.7 million in Q4 2025, and $211000.0 in Q3 2025.